November 1, 2016
Macrocyclics was contracted by Radiomedix and AREVA Med to produce the cGMP peptide conjugate that will be used in their collaborative clinical trial. RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212 Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) — RadioMedix Inc. (Houston TX) and
April 13, 2016
AREVA Med has launched operations at its second high-purity lead-212 (²¹²Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic Distribution and Purification Unit), this facility was officially opened today in the presence of local elected officials, AREVA Med Scientific Advisory Committee, as well as AREVA Group and AREVA Med executives and teams
January 21, 2016
AREVA Med’s second high-purity lead-212 (²¹²Pb) production facility is now well advanced in the construction and is expected to be operational, as scheduled, in the second quarter of 2016. Construction work began in September 2015 for this facility, known as the DDPU (Domestic Distribution and Purification Unit), which is located in Plano, Texas. This state-of-the-art
April 13, 2016 - Plano, Texas
Read AllJanuary 21, 2016 - Plano, Texas
Read AllMay 18, 2015 - Houston, Texas & Bethesda, Maryland
Read AllOctober 20, 2011 - Bethesda, Maryland
Read All
May 30 – June 1, 2017 / Kanazawa, Japan
Meet us at the 10th International Symposium on Targeted Alpha Therapy.
October 21-25, 2017 / Vienna, Austria
Please visit the Macrocyclics team at our booth (Hall X2, Booth #234) to learn more about our new products and peptide synthesis services. Also, this is a great opportunity to plan for upcoming projects and special chelating agent requirements.
June 23-26, 2018 / Philadelphia, PA
Please visit the Macrocyclics team at our booth (Booth #310) to learn more about our new products and peptide synthesis services. Also, this is a great opportunity to plan for upcoming projects and special chelating agent requirements.
